Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 3
2006 2
2007 3
2008 1
2009 1
2010 1
2011 3
2012 2
2013 4
2014 7
2015 6
2016 12
2017 11
2018 13
2019 17
2020 13
2021 17
2022 15
2023 15
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Results by year

Filters applied: . Clear all
Page 1
Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness-a protocol for a randomised controlled trial (ASTUTE trial).
Hazell M, Reeves B, Rogers CA, Pike K, Culliford L, Baos S, Lui MPY, Beare NAV, Pavesio C, Denniston AK, Wordsworth S, Keane PA, Wilson R, Folkard A, Peto T, Sharma SM, Dick A. Hazell M, et al. Among authors: wordsworth s. BMJ Open. 2024 Jan 24;14(1):e082246. doi: 10.1136/bmjopen-2023-082246. BMJ Open. 2024. PMID: 38267244 Free PMC article.
Population screening requires robust evidence-genomics is no exception.
Turnbull C, Firth HV, Wilkie AOM, Newman W, Raymond FL, Tomlinson I, Lachmann R, Wright CF, Wordsworth S, George A, McCartney M, Lucassen A. Turnbull C, et al. Among authors: wordsworth s. Lancet. 2024 Feb 10;403(10426):583-586. doi: 10.1016/S0140-6736(23)02295-X. Epub 2023 Dec 6. Lancet. 2024. PMID: 38070525 Review. No abstract available.
Cost-effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries.
Vellekoop H, Huygens S, Versteegh M, Szilberhorn L, Zelei T, Nagy B, Koleva-Kolarova R, Wordsworth S, Rutten-van Mölken M; HEcoPerMed consortium. Vellekoop H, et al. Among authors: wordsworth s. Per Med. 2023 Jul;20(4):321-338. doi: 10.2217/pme-2022-0070. Epub 2023 Sep 25. Per Med. 2023. PMID: 37746727 Free article.
137 results